Figure 4

Efficacy of ChAdOx1 MERS in dromedaries based on GE TCID₅₀/ml. Nasal swab samples from 1 to 14 days post challenge (d.p.c.) were assessed in absolute RT-qPCR quantification and the MERS-CoV viral genome equivalent (GE) to TCID₅₀/ml is reported. (A) The mean titres of MERS-CoV GE (TCID₅₀/ml) are reported from 1 to 14 days post challenge (d.p.c.) with SEM error bars for each group. (B) Areas under the curve (AUC) for the mean MERS-CoV GE (TCID₅₀/ml) titres measured from 1 to 14 d.p.c. are plotted for each group. +: Seropositive; −: seronegative; (C) control group; V: vaccinated group. The analysis of mixed model on the log-transformed MERS-CoV GE (TCID₅₀/ml) titres and fixed factors (d.p.c., seropositivity, and vaccine) shows that the vaccine was significant with p = 0.0059.